(NASDAQ:ATYR), LOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises aTyr Pharma, Inc., (“aTyr” or the “Company”) (NASDAQ: ATYR) investors off a class action on behalf of investors that bought securities between January 16, 2025 and September 12, 2025, inclusive (the “Class Period”). aTyr investors have until December 8, 2025 to […]
Portnoy Law Firm Announces Class Action on Behalf of aTyr Pharma, Inc. Investors GlobeNewswire October 23, 2025 LOS ANGELES, Oct. 23, 2025 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises aTyr Pharma, Inc., (“aTyr” or the “Company”) (NASDAQ: ATYR) investors off a class action on behalf of investors that bought securities between January 16, 2025
“Hypnotherapy for children is an effective and evidence-based psychological therapy tool. As an experienced licensed psychotherapist andhypnotherapist, I wanted to create a child-friendly hypnotherapy tool,” said an inventor, from Papillion, Nebraska, “so I invented the Remedy Tails. My design could offer an affordable, at-home alternative to prolonged and expensive in-office therapy.” https://mma.prnewswire.com/media/2099578/InventHelp_Logo_jpg_Logo.jpg The invention provides
Pomerantz LLP is investigating claims on behalf of investors of Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN). Such investors are advised to contact Danielle Peyton atnewaction@pomlaw.comor 646-581-9980, ext.7980. https://mma.prnewswire.com/media/2287619/Pomerantz_V3_Logo.jpg The investigation concerns whether Stride and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for
(Paris:CGM), PRESS RELEASE Quarterly financial information as of September 30, 2025IFRS – Regulated information – Not audited Cegedim: like-for-like revenue growth of 2.1% over 9 months is on target Revenue of EUR153.7 million in Q3 2025, up 0.5% Q3 growth engines: cloud, HR, digitalization and health & provident insurance solutions Cumulative 9M 2025 revenue of
(Paris:GBT), Revenue at September 30, 2025 Return to growth in Q3 2025 9-month revenue: EUR586.5 million, down 2.8% at CER1 and on a like-for-like basis2, largely due to the fall in activity in France An increase in Q3 of 2.6% at CER and on a like-for-like basis, underpinned by the acceleration of EluciremTM sales and
Cegedim: like-for-like revenue growth of 2.1% over 9 months is on target GlobeNewswire October 23, 2025 PRESS RELEASE Quarterly financial information as of September 30, 2025IFRS – Regulated information – Not audited Cegedim: like-for-like revenue growth of 2.1% over 9 months is on target Revenue of EUR153.7 million in Q3 2025, up 0.5% Q3 growth
Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025. Confirmation of all financial targets for 2025. GlobeNewswire October 23, 2025 Revenue at September 30, 2025 Return to growth in Q3 2025 9-month revenue: EUR586.5 million, down 2.8% at CER1 and on a like-for-like basis2, largely due to the fall in activity
(NASDAQ:WABC), SAN RAFAEL, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — The Board of Directors of Westamerica Bancorporation (NASDAQ: WABC) today declared a quarterly cash dividend of $0.46 per share on common stock outstanding to shareholders of record at the close of business November 3, 2025. The dividend is payable November 14, 2025. Chairman, President and
Westamerica Bancorporation Declares Quarterly Cash Dividend GlobeNewswire October 23, 2025 SAN RAFAEL, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — The Board of Directors of Westamerica Bancorporation (NASDAQ: WABC) today declared a quarterly cash dividend of $0.46 per share on common stock outstanding to shareholders of record at the close of business November 3, 2025. The